APA (7th ed.) Citation

J, M., SJ, S., E, P., C, V., A, S., A, R., . . . DS, M. (2026). IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort. Cancer communications (London, England), 46, 0015. https://doi.org/10.34133/cancomm.0015

Chicago Style (17th ed.) Citation

J, Martin-Broto, et al. "IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort." Cancer Communications (London, England) 46 (2026): 0015. https://doi.org/10.34133/cancomm.0015.

MLA (9th ed.) Citation

J, Martin-Broto, et al. "IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort." Cancer Communications (London, England), vol. 46, 2026, p. 0015, https://doi.org/10.34133/cancomm.0015.